HELPING THE OTHERS REALIZE THE ADVANTAGES OF LDN-27219 AS A CANCER DRUG CANDIDATE

Consensus sequence for tTG crosslinking substrates. Alignment of all glutamine-donor crosslinking substrates described in the Transdab databases demonstrates that aside from glutamine (Q at posture 0), There is certainly minor to no favoritism for different residues at up to five positions in advance of or following the glutamine residue being cros